Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases
- PMID: 22607798
- PMCID: PMC3360875
- DOI: 10.1016/j.chom.2012.04.004
Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases
Abstract
Only two decades ago antibodies to fungi were thought to have little or no role in protection against fungal diseases. However, subsequent research has provided convincing evidence that certain antibodies can modify the course of fungal infection to the benefit or detriment of the host. Hybridoma technology was the breakthrough that enabled the characterization of antibodies to fungi, illuminating some of the requirements for antibody efficacy. As discussed in this review, fungal-specific antibodies mediate protection through direct actions on fungal cells and through classical mechanisms such as phagocytosis and complement activation. Although mechanisms of antibody-mediated protection are often species-specific, numerous fungal antigens can be targeted to generate vaccines and therapeutic immunoglobulins. Furthermore, the study of antibody function against medically important fungi has provided fresh immunological insights into the complexity of humoral immunity that are likely to apply to other pathogens.
Copyright © 2012 Elsevier Inc. All rights reserved.
Figures

Similar articles
-
The protective role of immunoglobulins in fungal infections and inflammation.Semin Immunopathol. 2015 Mar;37(2):187-97. doi: 10.1007/s00281-014-0466-0. Epub 2014 Nov 18. Semin Immunopathol. 2015. PMID: 25404121 Review.
-
Antibody-mediated protection through cross-reactivity introduces a fungal heresy into immunological dogma.Infect Immun. 2007 Nov;75(11):5074-8. doi: 10.1128/IAI.01001-07. Epub 2007 Aug 20. Infect Immun. 2007. PMID: 17709417 Free PMC article. Review. No abstract available.
-
Immunological aspects of fungal pathogenesis.Eur J Clin Microbiol Infect Dis. 1990 Aug;9(8):567-79. doi: 10.1007/BF01967211. Eur J Clin Microbiol Infect Dis. 1990. PMID: 2209625 Review.
-
Nanoparticle-Based Mycosis Vaccine.Methods Mol Biol. 2017;1625:169-211. doi: 10.1007/978-1-4939-7104-6_13. Methods Mol Biol. 2017. PMID: 28584991
-
The efficacy of acquired humoral and cellular immunity in the prevention and therapy of experimental fungal infections.Med Mycol. 2000;38 Suppl 1:281-92. Med Mycol. 2000. PMID: 11204156 Review.
Cited by
-
New approaches in the development of a vaccine for mucosal candidiasis: progress and challenges.Front Microbiol. 2012 Aug 13;3:294. doi: 10.3389/fmicb.2012.00294. eCollection 2012. Front Microbiol. 2012. PMID: 22905033 Free PMC article.
-
Epitope-Based Immunoinformatic Approach on Heat Shock 70 kDa Protein Complex of Cryptococcus neoformans var. grubii.J Immunol Res. 2021 Aug 19;2021:9921620. doi: 10.1155/2021/9921620. eCollection 2021. J Immunol Res. 2021. PMID: 34471644 Free PMC article.
-
Single human B cell-derived monoclonal anti-Candida antibodies enhance phagocytosis and protect against disseminated candidiasis.Nat Commun. 2018 Dec 11;9(1):5288. doi: 10.1038/s41467-018-07738-1. Nat Commun. 2018. PMID: 30538246 Free PMC article.
-
Antibodies to Combat Fungal Infections: Development Strategies and Progress.Microorganisms. 2023 Mar 6;11(3):671. doi: 10.3390/microorganisms11030671. Microorganisms. 2023. PMID: 36985244 Free PMC article. Review.
-
Immunomodulation for the Treatment of Fungal Infections: Opportunities and Challenges.Front Cell Infect Microbiol. 2020 Sep 15;10:469. doi: 10.3389/fcimb.2020.00469. eCollection 2020. Front Cell Infect Microbiol. 2020. PMID: 33042859 Free PMC article. Review.
References
-
- Abadi J, Pirofski L. Antibodies reactive with the cryptococcal capsular polysaccharide glucuronoxylomannan are present in sera from children with and without HIV infection. J Infect Dis. 1999;180:915–919. - PubMed
-
- Allen HL, Deepe GS., Jr B cells and CD4-CD8− T cells are key regulators of the severity of reactivation histoplasmosis. J Immunol. 2006;177:1763–1771. - PubMed
-
- Allendoerfer R, Brunner GD, Deepe GS., Jr Complex requirements for nascent and memory immunity in pulmonary histoplasmosis. J Immunol. 1999;162:7389–7396. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 AI033142/AI/NIAID NIH HHS/United States
- R01 AI044374/AI/NIAID NIH HHS/United States
- R01 AI033774/AI/NIAID NIH HHS/United States
- R01 HL059842/HL/NHLBI NIH HHS/United States
- HL059842/HL/NHLBI NIH HHS/United States
- R01 AI052733/AI/NIAID NIH HHS/United States
- R37 AI033142/AI/NIAID NIH HHS/United States
- R01-AI044374/AI/NIAID NIH HHS/United States
- R01 AI045459/AI/NIAID NIH HHS/United States
- AI033142/AI/NIAID NIH HHS/United States
- AI033774/AI/NIAID NIH HHS/United States
- AI052733/AI/NIAID NIH HHS/United States
- R01-AI045459/AI/NIAID NIH HHS/United States
- U54 AI057158/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials